MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to regulation 47 of SEBI (LODR) regulations, 2015, kindly find enclosed newspaper advertisement pertaining to unaudited financial results for quarter and half year ended september 30, 2023 MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to regulation 30 of SEBI (LODR) regulations, 2015, the Company has uploaded the audio recording of investors/analysts meet for Q2FY24 financial performance and strategy update held today i.e. November 09, 2023 on the Company website MARKSANS PHARMA LTD. - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants.
Pursuant to regulation 32 of LODR, Please find enclosed a NIL statement of Deviation reviewed by audit committee for quarter ended September 30, 2023 MARKSANS PHARMA LTD. - 524404 - Quarterly And Half Yearly Results For Period Ended September 30, 2023
Quarterly and half yearly results MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release for Q2FY24 Financial results MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation for Q2FY24 MARKSANS PHARMA LTD. - 524404 - Board Meeting Outcome for Unaudited Consolidated And Standalone Financial Results For The Quarter And Half Year Ended September 30, 2023 Along With Limited Review Reports
Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and other regulations, if applicable, we hereby inform the Exchanges that the Board of Directors ('Board') of the Company at its Meeting held on November 09, 2023 has, inter alia, approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended September 30, 2023. The meeting commenced at 12:00 p.m. and concluded at 12:50 p.m. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives market authorization for the product Cyanocobalamin 50mg film coated tablets MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited hereby announces that its wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from USFDA for audit conducted in October 2023. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Marksans Pharma Limited has scheduled a conference call for analysts and investors on Thursday, November 09, 2023 at 5:30 p.m. (IST) on the unaudited (standalone and consolidated) financial results of the Company for the quarter and half year ended September 30, 2023